On Thursday, the data of the Ministry of Health of the Kingdom of Bahrain on the Russian Sputnik V vaccine was released by the Russian Direct Investment Fund. The vaccine demonstrated 94.3% high efficacy and safety in the country during the vaccination campaign.
The study was conducted in Bahrain following WHO guidelines which involved more than 5,000 subjects. The efficacy estimated was 94.3% after 14 days of administering the second dose. The data denotes high safety of Sputnik V with no serious adverse events associated with vaccination, no deaths related to the vaccination and also no cerebral vein thrombosis (CVT) cases after vaccination.
HE Faeqa Saaed Al-Saleh, Bahrain’s Minister of Health stated that the data confirmed high efficacy and safety of Sputnik V while it was used in Bahrain and this vaccine is one of the approved vaccines which is available free of charge to citizens and residents in the Kingdom.
He further said that Sputnik V played an important role in the Kingdom’s ongoing and successful vaccination campaign which has vaccinated 81% of the eligible population so far.
The CEO of the RDIF, Kirill Dmitriev asserted that the Russian vaccine has demonstrated efficacy of 94.3% and also confirmed high safety after data collected from a number of other countries where the population were vaccinated with it against coronavirus.